Fig. 2: Clinical significance of ITGA3 expression in relation to CTCs formation, tumor invasion, and prognosis in PDAC patients. | Cell Death & Disease

Fig. 2: Clinical significance of ITGA3 expression in relation to CTCs formation, tumor invasion, and prognosis in PDAC patients.

From: CAFs-derived LAM332 promotes CTCs formation and survival via ITGA3 and contributes to the metastasis of pancreatic ductal adenocarcinoma

Fig. 2: Clinical significance of ITGA3 expression in relation to CTCs formation, tumor invasion, and prognosis in PDAC patients.

A Representative images of IHC for ITGA3 in the invasive front and noninvasive front of the tumor. B Immunoreactive scores (IRS) were quantified for comparison between the two groups (n = 10 for noninvasive front, n = 10 for invasive front). C Multiplex immunofluorescence images showing the expression of ITGA3 and the detection of CTCs in the peritumoral vasculature. D Comparison of CTC counts in patients with different ITGA3 expression levels (plectin as a biomarker of CTCs in PDAC) (n = 10 for high ITGA3, n = 10 for low ITGA3). E Representative images of IHC for ITGA3 in primary PDAC and advanced PDAC. F The frequency of cases with the indicated scores of ITGA3 immunoreactivity (n = 36 for advanced PDAC, n = 24 for primary PDAC). G Kaplan‒Meier survival curves showing the correlation between the ITGA3 expression level and survival (OS and RFS) (n = 30 for ITGA3-high, n = 30 for ITGA3-low). H, I Forest plot of multivariate Cox regression analysis of OS and RFS in 60 patients with PDAC.

Back to article page